The unit will produce a range of organic molecules on a contractual basis, including specialty and fine chemicals, pharmaceutical intermediates and NCEs from the milligram to kilogram scale.
According to Chemir, whose custom chemical synthesis team was established in 1995, the new service enables clients to create innovative new products in plastics, polymers, coatings, agrochemicals and chemicals.
Laura Rainey, a spokesperson for Chemir, told Outsourcing-Pharma: “We offer a unique concentration on unusual projects, and clients retain all rights and intellectual property of their research,” adding: “Our close ties between our synthesis group and our cGMP analytical lab offer a unique opportunity for clients.”
The key benefit of Chemir’s Custom Synthesis service, according to Rainey, is “[the unit’s] focus on customer service, clear communication and problem solving. We take pride in clearly communicating our results to the client, and we welcome rush or emergency projects.”
Chemir’s Senior Laboratory Manager, Albert Lee, also explained that the unit will make impurities to help smaller-scale pharmaceutical manfacturers hone their toxin and contaminant detection techniques.
“Pharmaceutical products, whether they are APIs or medical devices, will have impurities,” said Dr Lee, adding that “identification of impurities led to the need for multigram quantities of these contaminants. We offered custom synthesis service to meet this need.”
Furthermore, Chemir’s pharmaceutical contract custom synthesis chemists, eight of whom are educated to Ph.D. level, are experienced in dealing with substances specified on the Drug Enforcement Agency’s list of Schedule I-IV controlled substances.
Scientific staff produce the custom-made compounds using a range of state-of-the-art analytical instrumentation, with multinuclie 400 MHz NMR, FTIR, DSC, and ICP, amongst others, situated on-site at Chemir’s laboratories in Maryland Heights, MO.